Cargando…
Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer
BACKGROUND: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is a genetic driver of prostate cancer. It is activated through a fusion with the androgen-responsive TMPRSS2 promoter in 50% of cases. There is therefore significant interest in developing novel therape...
Autores principales: | Li, Ling, Hobson, Lisa, Perry, Laura, Clark, Bethany, Heavey, Susan, Haider, Aiman, Sridhar, Ashwin, Shaw, Greg, Kelly, John, Freeman, Alex, Wilson, Ian, Whitaker, Hayley, Nurmemmedov, Elmar, Oltean, Sebastian, Porazinski, Sean, Ladomery, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493922/ https://www.ncbi.nlm.nih.gov/pubmed/32581342 http://dx.doi.org/10.1038/s41416-020-0951-2 |
Ejemplares similares
-
The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties
por: Jumbe, Samantha L., et al.
Publicado: (2018) -
Alternative Splicing in the Hippo Pathway—Implications for Disease and Potential Therapeutic Targets
por: Porazinski, Sean, et al.
Publicado: (2018) -
The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing
por: Luxton, Hayley J., et al.
Publicado: (2019) -
Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells
por: Bowler, Elizabeth, et al.
Publicado: (2018) -
SPHINX-Based Combination Therapy as a Potential Novel Treatment Strategy for Acute Myeloid Leukaemia
por: Wodi, Chigeru, et al.
Publicado: (2023)